What does payments of stock issuance costs mean?

Captures the cash outflows associated with the registration, underwriting, and legal processes required to issue new shares of common or preferred stock. These costs are directly deducted from the proceeds of equity offerings and represent the friction of accessing public capital markets. Investors analyze this metric to evaluate the cost-effectiveness of equity-based financing strategies.

Palvella Therapeutics PVLA Payments Of Stock Issuance Costs

Payments Of Stock Issuance Costs at other companies

Viridian Therapeutics, Inc.VRDN

——

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.86B+468%

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfStockIssuanceCosts.

The official record: Palvella Therapeutics’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's payments of stock issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's payments of stock issuance costs?: Palvella Therapeutics (PVLA) reported payments of stock issuance costs of $38.5K in Q4 2025.
What does payments of stock issuance costs mean?: Captures the cash outflows associated with the registration, underwriting, and legal processes required to issue new shares of common or preferred stock. These costs are directly deducted from the proceeds of equity offerings and represent the friction of accessing public capital markets. Investors analyze this metric to evaluate the cost-effectiveness of equity-based financing strategies.